Yaz Lawsuits Drop 5% As Bayer Increases Settlements With Victims

Monday, June 16, 2014

After two years and nearly $2 billion in settlements to victims of Yaz blood clots, German drug maker Bayer is finally seeing a drop in the number of lawsuits filed against their popular birth control drugs Yaz and Yasmin.

The Judicial Panel on Multidistrict Litigation, which oversees federal mass tort litigation against hundreds of allegedly dangerous products around the country, reported today that the number of pending Yaz lawsuits had dropped from 9,426 on April 15 to 8,919 as of June 16.

That’s a drop of more than 5% in recent months, the largest since lawsuits against Yaz began years ago. But it comes at a price: Bayer has now spent over $1.75 billion paying out settlements to more than 8,600 women and families.

The average Yaz settlement, according to Bayer, is around $200,000. And they are only considering cases involving deep vein thrombosis (DVT), pulmonary embolism, or stroke for women taking Yaz, Yasmin or a similar generic before mid-2012.

However, Bayer says they will continue to review lawsuits through 2014.

Lawyers are still helping those affected file a claim, and it costs nothing for help unless victims receive an award or settlement.

So far, Bayer says they have faced over 13,000 lawsuits from patients alleging Yaz side effects. However, this is still far less than the more than 20,000 blood clot injuries reported for Yaz or Yasmin to the FDA. Lawyers are surprised so many women have not yet taken advantage of the free help available for themselves and their families.



birth control

Other drugs and devices in the news:

Friday, August 9, 2019
Surgical Stapler
Did Surgical Staple Companies Hide Thousands of Injuries?

This past spring, the FDA issued a warning affecting the millions of patients each year that undergo routine gastrointestinal, gynecologic...

Friday, August 2, 2019
Invokana Gangrene Amputation
Federal Panel Adds Fournier's Gangrene to Crowded Invokana MDL Court

In the latest Invokana lawsuit update, DrugNews has learned that a federal judicial panel has transferred new cases alleging...

Get in touch with us.

Call, email or live chat with us today to see how we can help.

call DrugNews.net
Need a quick answer? Call us!
email DrugNews.net
Reach out to us by email.
live chat with DrugNews
We are here to help now